Vimarsana
Biggest News Aggregation in the World

Page 4 - Jay Mathews News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jay Mathews. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jay Mathews Today - Breaking & Trending Today

'Sleepless in Seattle' celebrates 30th anniversary: The cast then and now - Vimarsana News

'Sleepless in Seattle' celebrates 30th anniversary: The cast then and now

The classic romantic comedy "Sleepless in Seattle" is celebrating its 30th anniversary. Here is a look at where some of the movie's biggest stars, including Tom Hanks and Meg Ryan, are now.

Murder on Connor Ave, no answers now a year later - Vimarsana News

Murder on Connor Ave, no answers now a year later

JOPLIN, Mo. — One year ago in the Gray Neighborhood of Joplin, gunshots rang out near 5th and Connor Ave. So many and so loud dozens reported hearing them.

Akura Medical Announces Successful First-in-Human Use of its High Performance Mechanical Thrombectomy Platform - Vimarsana News

Akura Medical Announces Successful First-in-Human Use of its High Performance Mechanical Thrombectomy Platform

Initial cases, proctored by 2 leading US interventionalists, mark the first use of mechanical thrombectomy for pulmonary embolism in the Republic ...

MedAlliance enrolls first US patient into its third FDA IDE Study: SFA SELUTION4SFA - Vimarsana News

MedAlliance enrolls first US patient into its third FDA IDE Study: SFA SELUTION4SFA

Geneva [Switzerland], May 5 (ANI/PRNewswire): The first US patient has been enrolled in the SELUTION4SFA Sirolimus DEB study by Dr Arthur Lee at the Cardiac & Vascular Institute in Florida. This study evaluates SELUTION SLR in the treatment of occlusive disease of the superficial femoral artery (SFA) and proximal popliteal artery (PPA) and has been designed to support FDA approval. It follows Investigational Device Exemption (IDE) approval in the US in August 2022. SELUTION SLR is the first and only limus release drug-eluting balloon (DEB) to receive FDA IDE approval for SFA and PPA indica...

Related Topics:
United StatesSwitzerland GeneralManatee Memorial HospitalRichard KenyonJay MathewsArthur LeeVascular InstituteCell Adherent TechnologyInvestigational Device ExemptionCo Principal InvestigatorMiddle EastGeneva SwitzerlandAy 5 Ani Prnewswire The First Us Patient Has Been Enrolled In Selution4sfa Sirolimus Deb Study By Dr Arthur Lee At Cardiac Amp Vascular Institute Florida This Evaluates Selution Slr Treatment Of Occlusive Disease Superficial Femoral Artery Sfa And Proximal Popliteal Ppa Designed To Support Fda Approval It Follows Investigational Device Exemption Ide August 2022 Is Only Limus Release Drug Eluting Balloon Receive For Indications Being Conducted Over 30 Centers Plus An Additional 10 Worldwide Will Enroll 300 PatientsIth The Aim Of Demonstrating Superiority Selution Slr Over Balloon Angioplasty Poba Primary Efficacy Endpoint Is Patency Target Lesion At 12 Months And Safety Freedom From Death 30 Days Enrollment Into Study Will Be Complete By End 2023 Quot We Are Excited To Introduce First Sirolimus Deb Us PatientsNd Look Forward Toa Rapid Enrollment Of This Important StudyUot Commented Dr Jay MathewsCo Principal InvestigatorManatee Memorial HospitalLorida Quot We Hope To Learn How This Technology Can Potentially Benefit Patients With Complex Peripheral Arterial Disease Are Pleased Be Enrolling Our Third Ide Study In UsNd Look Forward To The Results Of These Three Studies As Well Future Ide ComeUot Added Jeffreyb JumpHairman And Ceo Of Medalliance Selution Slr Was Awarded Ce Mark Approval For The Treatment Coronary Artery Disease In May 2020 First Drug Eluting Balloon Company To Receive Fda Breakthrough Designation Status CurrentlyHree Ide Clinical Studies Are Evaluating Selution Slr In The Us Clti Patients With Btk Disease Sfa Ppa And Coronary Isr AdditionEdalliance Received Ide Approval For De Novo Coronary Artery Lesions In January 2023 This Complements The Substantial Experience That Company Has Gained With Selution Denovo And Success Trials Europe Medalliance 39s Unique Deb Technology Involves Microreservoirs Which Containa Combination Of Biodegradable Polymer Intermixed Anti Restenotic Drug SirolimusPplied Asa Coating On The Surface Of An Angioplasty Balloon These Microreservoirs Provide Controlled And Sustained Release Drug For Up To 90 Days Medalliance 39s Proprietary Cat Cell Adherent Technology Enables Be Coated Onto Balloons Efficiently Transferred Adhere Vessel Lumen When Delivered Via Expansion Selution Slr Is Commercially Available In Europe
Branford Community Dining Room auction, dinner, to raise funds - Vimarsana News

Branford Community Dining Room auction, dinner, to raise funds

Local artists donate works for auction and dinner to benefit Branford Community Dining Room.